Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Clinical Pharmacology and Therapeutics
Journal
Overview
Identity
Overview
Publication Venue For
Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y
12
Inhibitor Prescribing After Percutaneous Coronary Intervention
. 113:615-623.
2023
Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions, and Pharmacogenetics
. 113:585-599.
2023
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update
. 112:959-967.
2022
ISPE-Endorsed Guidance in Using Electronic Health Records for Comparative Effectiveness Research in COVID-19: Opportunities and Trade-Offs
. 112:990-999.
2022
Warfarin Dosing in Patients With CYP2C9*5 Variant Alleles
. 111:950-955.
2022
Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment-Resistant Epilepsy
. 110:1368-1380.
2021
Translational Pharmacogenomics: Discovery, Evidence Synthesis and Delivery of Race-Conscious Medicine
. 110:909-925.
2021
Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies
. 110:723-732.
2021
Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems
. 110:179-188.
2021
Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development
. 110:64-68.
2021
Effects of NT5C2 Germline Variants on 6-Mecaptopurine Metabolism in Children With Acute Lymphoblastic Leukemia
. 109:1538-1545.
2021
Thromboembolic and Hemorrhagic Outcomes in the Direct Oral Anticoagulant Trials Across the Spectrum of Kidney Function
. 109:1593-1605.
2021
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
. 109:705-715.
2021
Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants
. 109:253-262.
2021
Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis
. 107:1420-1433.
2020
Pharmacodynamics of Glyburide, Metformin, and Glyburide/Metformin Combination Therapy in the Treatment of Gestational Diabetes Mellitus
. 107:1362-1372.
2020
Innovations in Targeted Anti-Adhesion Treatment for Sickle Cell Disease
. 107:140-146.
2020
Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals
. 105:1477-1491.
2019
Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy
. 104:664-674.
2018
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update
. 102:397-404.
2017
Precision Medicine at the University of Alabama at Birmingham: Laying the Foundational Processes Through Implementation of Genotype-Guided Antiplatelet Therapy
. 102:493-501.
2017
Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait
. 101:373-381.
2017
Pharmacokinetics, pharmacodynamics, and safety of lisinopril in pediatric kidney transplant patients: Implications for starting dose selection
. 98:25-33.
2015
Helicase-primase as a target of new therapies for herpes simplex virus infections
. 97:66-78.
2015
The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach
. 96:380-389.
2014
Network medicine: Finding the links to personalized therapy
. 94:613-616.
2013
Erratum: Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects (Clinical Pharmacology and Therapeutics (1995) 58 (44-53) DOI: 10.1016/0009-9236(95)90071-3)
. 89:320.
2011
Determination of appropriate dosing of influenza drugs in pediatric patients
. 88:704-707.
2010
Treatment of herpes simplex virus infections in pediatric patients: Current status and future needs
. 88:720-724.
2010
Integration of genetic, clinical, and INR data to refine warfarin dosing
. 87:572-578.
2010
Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin
. 83:312-321.
2008
Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients
. 83:281-287.
2008
New pre-pandemic influenza vaccines: An egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice
. 82:665-671.
2007
Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation
. 81:867-872.
2007
The role of public policy in treating the epidemic of global obesity
. 81:772-775.
2007
Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis
. 72:546-555.
2002
Pharmacokinetic strategies for concentration-targeted therapy with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV)
. 65:161.
1999
Concentration-controlled zidovudine therapy
. 64:331-338.
1998
Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline
. 61:476-487.
1997
Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects
. 58:44-53.
1995
Linear single‐dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections
. 53:15-21.
1993
Pharmacokinetics of esmolol and ASL-8123 in renal failure
. 45:321-327.
1989
Rapid development of enhanced clearance after high-dose cyclophosphamide
. 44:622-628.
1988
Enalapril in low-renin essential hypertension
. 34:297-302.
1983
Lofexidine and clonidine in moderate essential hypertension
. 30:752-757.
1981
Plasma levels and urinary excretion of vidarabine after repeated dosing
. 27:690-696.
1980
Acyclovir kinetics after intravenous infusion
. 26:718-728.
1979
Identity
International Standard Serial Number (issn)
0009-9236
Electronic International Standard Serial Number (eissn)
1532-6535